Cargando…

Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy

Sudden cardiac death (SCD) is the most devastating complication in hypertrophic cardiomyopathy (HCM). The implantable cardioverter–defibrillator (ICD) has proven to be effective in SCD prevention in several clinical scenarios. In HCM population, it has demonstrated to successfully abort life-threate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sanchez, Diego Jimenez, Lozano, Ignacio Fernández
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Magdi Yacoub Heart Foundation 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209444/ https://www.ncbi.nlm.nih.gov/pubmed/30393643 http://dx.doi.org/10.21542/gcsp.2018.31

Ejemplares similares

Role of Implantable Cardioverter Defibrillators in the Treatment of Hypertrophic Cardiomyopathy
por: Ghosh, Joydeep, et al.
Publicado: (2005)

Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience
por: Weinstock, Jonathan, et al.
Publicado: (2016)

Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
por: Goldstein, Sarah A., et al.
Publicado: (2023)

Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator
por: Park, Yae Min
Publicado: (2023)

Anesthesia in a Child with Newly Diagnosed Hypertrophic Cardiomyopathy for Placement of Implantable Cardioverter Defibrillator
por: Kumar, Rajnish, et al.
Publicado: (2018)

Higher defibrillation threshold in methamphetamine cardiomyopathy patients with implantable cardioverter-defibrillator
por: Malhotra, Rakesh, et al.
Publicado: (2017)

Living with hypertrophic cardiomyopathy and an implantable defibrillator
por: Magnusson, Peter, et al.
Publicado: (2017)

Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention
por: Yazaki, Kyoichiro, et al.
Publicado: (2021)

High-Risk Apical Hypertrophic Cardiomyopathy Requiring an Implantable Cardioverter-Defibrillator: A Case Report of an Overlooked Etiology
por: Rathore, Azeem, et al.
Publicado: (2023)

Predictors of Implantable Cardioverter-Defibrillator Use in Patients with Ischemic Cardiomyopathy
por: Kelly, Ryan, et al.
Publicado: (2010)

Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy
por: Higgins, Angela Y., et al.
Publicado: (2020)

Implantable cardioverter-defibrillators /
Publicado: (1994)

Implantable cardioverter-defibrillator implantation should be considered in high-risk patients with apical hypertrophic cardiomyopathy as the same manner with the septal type
por: Park, Y M, et al.
Publicado: (2023)

Implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy: a need or not?
por: de Groot, Joris R.
Publicado: (2023)

Implantable cardioverter defibrillator in nonischemic cardiomyopathy: A systematic review and meta‐analysis
por: Khan, Safi U., et al.
Publicado: (2017)

Obstetric hemorrhage in a case of hypertrophic obstructive cardiomyopathy with automatic implantable cardioverter defibrillator: Anaesthesia and intensive care management
por: Mishra, Sandeep Kumar, et al.
Publicado: (2016)

Atrial fibrillation deteriorates tricuspid regurgitation following implantable cardioverter defibrillator lead placement in patient with hypertrophic obstructive cardiomyopathy
por: Mohri, Takato, et al.
Publicado: (2017)

Progressive electrical remodeling in apical hypertrophic cardiomyopathy leading to implantable cardioverter-defibrillator sensing failure during ventricular fibrillation
por: Fleeman, Blake E., et al.
Publicado: (2016)

Natural language processing of implantable cardioverter-defibrillator reports in hypertrophic cardiomyopathy: A paradigm for longitudinal device follow-up
por: Siontis, Konstantinos C., et al.
Publicado: (2021)

Programming implantable cardioverter/defibrillators and outcomes
por: Horlbeck, Fritz W., et al.
Publicado: (2015)

Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with implantable cardioverter-defibrillators with ischemic cardiomyopathy versus nonischemic cardiomyopathy at 33-month follow-up
por: Gandhi, Kaushang, et al.
Publicado: (2010)

Defibrillation Testing of the Implantable Cardioverter Defibrillator: When, How, and by Whom?
por: Pires, Luis A
Publicado: (2007)

Deactivation of implantable cardioverter-defibrillators
por: Wan, Darryl, et al.
Publicado: (2021)

Inappropriate shock from delayed T-wave oversensing by a subcutaneous implantable cardioverter-defibrillator after septal myectomy for hypertrophic cardiomyopathy
por: Salgado, Benjamin C., et al.
Publicado: (2018)

Implantation of Implantable Cardioverter Defibrillators in Kazakhstan
por: Begisbayev, Temirkhan, et al.
Publicado: (2022)

A Pregnancy with Severe Hypertrophic Obstructive Cardiomyopathy after Surgery for an Implantable Cardioverter Defibrillator: A Case Report and Literature Review
por: Mitsui, Takashi, et al.
Publicado: (2016)

The subcutaneous implantable cardioverter-defibrillator should be considered for all patients with an implantable cardioverter-defibrillator indication
por: Tan, Jian Liang, et al.
Publicado: (2022)

Quality of Life in Patients with Implantable Cardioverter Defibrillators
por: Francis, Johnson, et al.
Publicado: (2006)

Wearable cardioverter-defibrillator as bridging to ICD in pediatric hypertrophic cardiomyopathy with myocardial bridging – a case report
por: Kurath-Koller, Stefan, et al.
Publicado: (2020)

Subcutaneous implantable cardioverter-defibrillator placement in a patient with a preexisting transvenous implantable cardioverter-defibrillator
por: Jazayeri, Mohammad-Ali, et al.
Publicado: (2017)

Performance of the PRIMaCY sudden death risk prediction model for childhood hypertrophic cardiomyopathy: implications for implantable cardioverter-defibrillator decision-making
por: Norrish, Gabrielle, et al.
Publicado: (2023)

Impact of implantable cardioverter defibrillator on survival in patients with non‐ischemic dilated cardiomyopathy
por: Kataoka, Naoya, et al.
Publicado: (2023)

Response: Impact of implantable cardioverter defibrillator on survival in patients with nonischemic dilated cardiomyopathy
por: Salehi Omran, Hossein, et al.
Publicado: (2023)

Relation of multicenter automatic defibrillator implantation trial implantable cardioverter-defibrillator score with long-term cardiovascular events in patients with implantable cardioverter-defibrillator
por: Uslu, Abdulkadir, et al.
Publicado: (2018)

Implantable Cardioverter-Defibrillator for Primary Prevention in Asia
por: Younis, Arwa, et al.
Publicado: (2023)

The subcutaneous implantable cardioverter defibrillator––review of the recent data
por: Westerman, Stacy B, et al.
Publicado: (2018)

Remote Monitoring of Implantable Cardioverter Defibrillator
por: Reynolds, Dwight W, et al.
Publicado: (2006)

The Subcutaneous Implantable Cardioverter-Defibrillator: Not For All
por: Nair, Krishnakumar, et al.
Publicado: (2014)

Driving restrictions in patients with implantable cardioverter defibrillators and pacemakers
por: Watanabe, Eiichi, et al.
Publicado: (2017)

Subcutaneous Implantable Cardioverter Defibrillator: A Contemporary Overview
por: Guarracini, Fabrizio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vu71tok9nsmmmuhf3o8jc0lsmm